NovaBay Pharmaceuticals — a nanocap with roughly $30 million in market cap selling wound-care products — has fully abandoned healthcare and rebranded as Stablecoin Development Corporation (ticker: SDEV), effective April 3, 2026 on NYSE American.

The pivot follows a $134 million private placement closed in January 2026, backed by Framework Ventures, Tether Investments, R01 Fund LP, and Sky Frontier Foundation. The company deployed the bulk of those proceeds into SKY, the governance token of Sky Protocol (the DeFi platform formerly known as MakerDAO), which issues the USDS stablecoin.

What They Built

As of March 16, SDEV holds approximately 2.06 billion SKY tokens — 8.78% of the entire supply — worth roughly $147 million. About 1.09 billion tokens were purchased on the open market at an average of $0.065 per token. The rest arrived as in-kind consideration alongside $25 million in cash and $51 million in stablecoins from the original placement.

The company is now actively staking its holdings and has accumulated roughly 26.6 million SKY in rewards. Sky's staking rate currently exceeds 10% annually.

CEO Michael Kazley framed the move as building "the premier public market vehicle to access cash flows within the growing stablecoin economy," describing the firm as an on-chain holding company focused on protocol-level digital asset participation.

Why It Matters

SDEV joins a growing list of public companies adopting crypto treasury strategies — but the pharma-to-DeFi pivot is one of the more extreme examples. Rather than adding Bitcoin to a balance sheet, the company has restructured its entire identity around a single DeFi protocol, concentrating ownership of nearly 9% of its governance token. That level of concentration gives SDEV meaningful influence over Sky Protocol's governance decisions going forward.